Active Ingredient History
Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anesthesia (Phase 4)
Anesthesia, Conduction (Phase 4)
Atracurium (Phase 4)
Cefazolin (Phase 4)
Drug Hypersensitivity (Phase 4)
Intraocular Pressure (Phase 2)
Intubation (Phase 4)
Intubation, Intratracheal (Phase 2/Phase 3)
Kidney Diseases (Phase 4)
Laparoscopy (Phase 4)
Mastectomy, Radical (Phase 1/Phase 2)
Morphine (Phase 4)
Myoclonus (Phase 4)
Nadroparin (Phase 4)
Neuromuscular Blockade (Phase 4)
Obesity (Phase 4)
Osteoarthritis, Hip (Phase 4)
Osteoarthritis, Knee (Phase 4)
Pain, Postoperative (Phase 4)
Perfusion (Phase 2/Phase 3)
Postoperative Nausea and Vomiting (Phase 4)
Premedication (Phase 2/Phase 3)
Vision, Ocular (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue